Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$XXII Low Nicotine Tobacco Products. Think we get a bounce here this week...
HRAL 4 yeaR weeklY…
https://schrts.co/AtAkXIYw
HRAL is a thinY mini…
Outstanding Shares
379,661,147
09/20/2024
Restricted
37,574,169
09/20/2024
Unrestricted
342,086,978
09/20/2024
Held at DTC
342,057,661
09/20/2024
Float
257,057,671
11/24/2023
Nice, HRAL… .00065 catching hiTs… looking to bust the .0007sss…
https://schrts.co/PSGSyPQG
$SILVER going to ride that uPPer bollie line like no ones business… Gold bussn’…
https://schrts.co/MbaSSEEK
NLSP .1510 on the inverted haMMer, and the daily psar fliPPed to the Bullish side to boot, on Stellar Volume surge…
https://schrts.co/jVDMsvDY
$IGPK
$IGPK Strong close to the day Friday tested .01 With all indicators curling North expect a strong open to the week.. pic.twitter.com/IgEFIAMH0R
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 22, 2024
$BMXI
$BMXI Continues to trade in tight formation while it holds strong above the 200 day MA..a close above the 50 day MA and see a nice push off.. pic.twitter.com/urBZYs9ZbP
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 22, 2024
$BASA
$BASA Strong breakout of late has been getting attention..continues to gain strength at these levels.. pic.twitter.com/5TbfeejMeo
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 22, 2024
BNCM - BNCM Announces that DELEX ICU FORUMS has reached a Global Audience of almost 200,000 Healthcare Professionals
September 16th, 2024; BNCM is excited to announce that the ICU (Intensive Care Unit) Forums conducted by DELEX have reached a Global Audience of almost 200,000 Healthcare Professionals.
$VINO Gaucho Holdings Optimizes Costs Amidst Argentine Economic Overhaul
https://finance.yahoo.com/news/gaucho-holdings-optimizes-costs-amidst-151500728.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$AXXA
$AXXA Quiet time is a prime time for shares before positive news jump starts this near perfect bottom play as support at .001 remains strong..Pop the 200 day MA at .0015 and watch the fireworks.. pic.twitter.com/bW5xYvzXSb
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 22, 2024
$MONI
$MONI Continues to make its way up the chart..volume remains strong with lots of upside to this one.. pic.twitter.com/xtb7mmmh2B
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 22, 2024
$AUTR micro float https://www.otcmarkets.com/stock/AUTR/security
NLSP… Daily psar flipped to the Bullish Buy side, after quite a span of time…
https://schrts.co/nsGsXmAU
Just got $IGPK .0083 buying picking up..
$CBDW and Adnexus partnership news...
https://finance.yahoo.com/news/adnexus-biotechnologies-partners-1606-corp-120000325.html
$MONI Strong buys kicking in..looking for .03 test..
RR...............VERB.................................https://www.stockscores.com/charts/charts/?ticker=RR
https://www.stockscores.com/charts/charts/?ticker=VERB
$MONI
$MONI Strong volume continues to take this higher as it looks ready to hit new highs.. pic.twitter.com/CYnWeptLM9
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 20, 2024
$SILVER $31.42… NICE daily Bullish Engulfing Candle…
https://schrts.co/AVsXpbZg
NLSP…
"AMENDMENT TO THE
NLS PHARMACEUTICS LTD.
COMMON STOCK PURCHASE WARRANTS
September 16, 2024
“This Amendment No. 1, dated September 16, 2024 (the “Effective Date”), to each of the following four common stock purchase warrants (the “Amendment”), issued by NLS Pharmaceuticals Ltd, a Swiss corporation (the “Company”), and each issued on or about (a) January 29, 2021, to Armistice Capital Master Fund Ltd. (“ACMF” or the “Holder” or the “Investor”) to purchase 500,000 shares of the Company’s common stock, par value CHF 0.02 (“Common Stock”), containing an exercise price of $4.15 per share (the “January 2021 Warrant”); (b) April 25, 2022, to ACMF to purchase 2,163,462 shares of Common Stock, containing an exercise price of $1.04 per share (the “April 2022 Warrant”); (c) March 22, 2024, to AMCF, to purchase 1,750,000 shares of Common Stock, containing an exercise price of $0.25 per share (the “March 2024 Warrant”); and (d) July 1, 2024, to ACMF to purchase 2,500,000 shares of Common Stock, containing an exercise price of $0.24 per share (the “June 2024 Warrant”, and together with the January 2021 Warrant, April 2022 Warrant and March 2024 Warrant, the “Existing Warrants”, and each a “Warrant”).”
https://www.otcmarkets.com/filing/html?id=17845694&guid=G2L-kWrdbxRXB3h
On September 18, 2024, NLS Pharmaceutics Ltd., or the Registrant, convened an extraordinary shareholders’ meeting, or the Meeting. At the Meeting, a quorum was present, and the shareholders of the Registrant approved all agenda items as originally proposed.
The Report on Form 6-K is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-262489, and 333-268690 and 333-269220), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.”"
NLSP .1369... insiders own a good 36%, Daily psar kissing to fliP to the Upside, on the doJi...
https://schrts.co/rXTZqrSw
TDRK .00995… Bullish Marubozu candlestick today, with: the full stochastics crossed to the uPside, and pinching in here…
https://schrts.co/IbpFTMrR
$MONI Up 12 percent and closing strong here..
Took $MONI .02 on the lunch pullback..like this to test hod into the close..
$SHMP
$SHMP Strong push off bottom here.. pic.twitter.com/WzQaAI8xy3
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 19, 2024
$KNOS
$KNOS Continues on a nice upswing..like how dips get bought up.. pic.twitter.com/9yCYw0mGm4
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 19, 2024
$BASA
$BASA Huge breakout here with plenty of room to run.. pic.twitter.com/rB2NPfTYWR
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 19, 2024
MONI
$MONI Chart remains strong as it bounced off the 20 day MA like a champ.. pic.twitter.com/SszKy4bEkm
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 19, 2024
$CUBT
$CUBT Strong volume kicking this higher..with a test of the 200 day MA is looming.. pic.twitter.com/QJGw8uYofp
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 18, 2024
$ZHUD
$ZHUD Continues to hold strong above the 20 day MA looking to see if it can push off and breaks to new highs.. pic.twitter.com/tcKEB6DyXk
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 18, 2024
$ADHC
$ADHC.. a sleeping giant here.. https://t.co/R7ffxGp2Bw
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 17, 2024
$ADHC Just slapped green here..wants to test recent highs..
$CBDW 1606 Corp. (OTC PINK:CBDW) (the "Company" or "1606") is pleased to announce it has signed a Letter of Intent to acquire a strategic stake in Adnexus Biotechnologies Inc., a pioneering company in Artificial Intelligence-driven innovations for early drug discovery and infectious disease research.
https://www.accesswire.com/918717/adnexus-biotechnologies-partners-with-1606-corp-for-strategic-investment-to-revolutionize-ai-driven-drug-discovery
$ELTP
$ELTP Freight train here..looks like next stop .50.. pic.twitter.com/grLmilmho9
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 17, 2024
$LDDFF
Liberty Defense Receives Follow on Contract Award from Prestigious US Laboratory
https://www.newswire.ca/news-releases/liberty-defense-receives-follow-on-contract-award-from-prestigious-us-laboratory-891448597.html
https://www.reddit.com/r/LibertyDefense/s/t10WH5BXEd
“
is pleased to announce that it has received a follow on contract award to support a high profile security screening program for high throughput mass transit systems. As previously announced, the Company delivered a HEXWAVE™ system to be integrated into a larger layered security system implementation currently under development. Liberty will be integrating a multi sensor application from the HEXWAVE to this platform to enhance the performance of the layered security approach for this program.
…
“We continue to see demand for the HEXWAVE and it’s multi sensor capabilities across various market verticals,” says Liberty CEO Bill Frain. “This is a perfect implementation for the HEXWAVE as we can provide multiple forms of data to enhance the detection and overall performance of an integrated security screening platform.”
Liberty has deployed its HEXWAVE technology for aviation screening, correctional facilities, protection of national laboratories, and other critical infrastructure applications. “
🤯😂
“
is pleased to announce that it has received a follow on contract award to support a high profile security screening program for high throughput mass transit systems. As previously announced, the Company delivered a HEXWAVE™ system to be integrated into a larger layered security system implementation currently under development. Liberty will be integrating a multi sensor application from the HEXWAVE to this platform to enhance the performance of the layered security approach for this program.
…
“We continue to see demand for the HEXWAVE and it’s multi sensor capabilities across various market verticals,” says Liberty CEO Bill Frain. “This is a perfect implementation for the HEXWAVE as we can provide multiple forms of data to enhance the detection and overall performance of an integrated security screening platform.”
Liberty has deployed its HEXWAVE technology for aviation screening, correctional facilities, protection of national laboratories, and other critical infrastructure applications. “
Post from Liberty Defense (@LibDefense) Liberty Defense (@LibDefense) posted at 8:15 AM on Thu, Sep 12, 2024: NEWS: Liberty Defense Receives Follow on Contract Award from Prestigious US Laboratory
NEWS: https://t.co/eqJU9SKlZR
$SCAN.V $LDDFF
SecurityDetection #AI #TouchlessScreening #AItechnology #SecurityScreening #ThreatDetection #Security #AirportSecurity #transitsecurity
(
)NEWS: Liberty Defense Receives Follow on Contract Award from Prestigious US Laboratory
— Liberty Defense (@LibDefense) September 12, 2024
NEWS: https://t.co/eqJU9SKlZR$SCAN.V $LDDFF #SecurityDetection #AI #TouchlessScreening #AItechnology #SecurityScreening #ThreatDetection #Security #AirportSecurity #transitsecurity
The Orange County Sheriff’s Department is piloting the VR headsets to create a virtual version of its crime centers, where cops monitor surveillance data in real time.
— Forbes (@Forbes) September 15, 2024
Read more: https://t.co/EQHyBejgfq pic.twitter.com/EdT9ByIL2I
Good morning everyone..
$HYSR Continues on the upswing here..would like to see support start to build around.03 now… pic.twitter.com/cRrinRbhng
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 17, 2024
$HIRU we heard from the head office in Qatar re FAQ questions of shareholders as per X tweets & updates promised. The Co held a board meeting where several material & significant positive resolutions were passed!. Full details will be released via filings and or official PR this week.
$HIRU we heard from the head office in Qatar re FAQ questions of shareholders as per X tweets & updates promised. The Co held a board meeting where several material & significant positive resolutions were passed!. Full details will be released via filings and or official PR this…
— Hiru Mining (@HIRUMining) September 16, 2024
$AGBA - Triller $4 Billion Merger: Elevating Shareholder Value to New Heights – Immediately and for the Longer Term
$ADHC
$ADHC Chart sitting right on the 20 day MA .. looks like prime spot for shares as it looks to push off and test recent highs.. pic.twitter.com/Xi5e1Lw1Bi
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) September 16, 2024
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
"How NRx Could Upend the Fight Against Depression and Suicide"
RADNOR, Pa., Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found here. The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
For more information, please visit http://www.nrxpharma.com.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL03022&sd=2024-09-11 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-featured-on-psychiatristcom-302244304.html
SOURCE NRx Pharmaceuticals, Inc.
Followers
|
1315
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
65118
|
Created
|
10/01/14
|
Type
|
Free
|
Moderator TommyBoyTrader9460 | |||
Assistants powerbattles doogdilinger SidewaysTrader KICK1 BLULLISH |
Posts Today
|
1
|
Posts (Total)
|
65118
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |